(Q43801101)

26 November 2017

title

Characteristics and mechanisms of azithromycin accumulation and efflux in human polymorphonuclear leukocytes (English)

1 reference

26 November 2017

0 references

Hand WL

1

1 reference

26 November 2017

Hand DL

series ordinal

2

1 reference

26 November 2017

language of work or name

1 reference

1 November 2001

1 reference

International Journal of Antimicrobial Agents

26 November 2017

published in

1 reference

26 November 2017

volume

18

1 reference

26 November 2017

issue

5

1 reference

26 November 2017

page(s)

419-425

1 reference

Azithromycin versus ceftriaxone for the treatment of uncomplicated typhoid fever in children

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900430-7

7 January 2021

Intracellular activity of azithromycin against bacterial enteric pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900430-7

7 January 2021

Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900430-7

7 January 2021

Advances in the prevention and treatment of Mycobacterium avium disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900430-7

7 January 2021

Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamyd

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900430-7

7 January 2021

Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900430-7

7 January 2021

Rationale and design of a secondary prevention trial of antibiotic use in patients after myocardial infarction: the WIZARD (weekly intervention with zithromax [azithromycin] for atherosclerosis and its related disorders) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900430-7

7 January 2021

Description and status of the azithromycin and coronary events study (ACES).

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900430-7

7 January 2021

The pharmacokinetics of azithromycin in human serum and tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900430-7

7 January 2021

Correlation of the extravascular pharmacokinetics of azithromycin with in-vivo efficacy in models of localized infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900430-7

7 January 2021

Relationship of high tissue concentrations of azithromycin to bactericidal activity and efficacy in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900430-7

7 January 2021

In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900430-7

7 January 2021

The significance of serum vs tissue levels of antibiotics in the treatment of penicillin-resistant Streptococcus pneumoniae and community-acquired pneumonia: are we looking in the wrong place?

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900430-7

7 January 2021

Pharmacological considerations in the emergence of resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900430-7

7 January 2021

In vitro and in vivo intraleukocytic accumulation of azithromycin (CP-62, 993) and its influence on ex vivo leukocyte chemiluminescence

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900430-7

7 January 2021

Uptake of azithromycin by human monocytes and enhanced intracellular antibacterial activity against Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900430-7

7 January 2021

Azithromycin pharmacokinetics and intracellular concentrations in Legionella pneumophila-infected and uninfected guinea pigs and their alveolar macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900430-7

7 January 2021

Requirements for intracellular accumulation and release of clarithromycin and azithromycin by human phagocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900430-7

7 January 2021

Uptake of azithromycin by various cells and its intracellular activity under in vivo conditions

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900430-7

7 January 2021

Antibiotic entry into human polymorphonuclear leukocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900430-7

7 January 2021

Effects of phagocytosis on antibiotic and nucleoside uptake by human polymorphonuclear leukocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900430-7

7 January 2021

Membrane transport of clindamycin in alveolar macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900430-7

7 January 2021

Contrasts between phagocyte antibiotic uptake and subsequent intracellular bactericidal activity

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900430-7

7 January 2021

The entry of antibiotics into human monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900430-7

7 January 2021

Entry of roxithromycin (RU 965), imipenem, cefotaxime, trimethoprim, and metronidazole into human polymorphonuclear leukocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900430-7

7 January 2021

Effect of phagocyte membrane stimulation on antibiotic uptake and intracellular bactericidal activity

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900430-7

7 January 2021

Uptake of antibiotics by human polymorphonuclear leukocyte cytoplasts

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900430-7

7 January 2021

Alkalinizing the intralysosomal pH inhibits degranulation of human neutrophils

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900430-7

7 January 2021

Interactions of dirithromycin with human polymorphonuclear leukocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900430-7

7 January 2021

Influence of pentoxifylline and its derivatives on antibiotic uptake and superoxide generation by human phagocytic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900430-7

7 January 2021

Uptake, accumulation, and egress of erythromycin by tissue culture cells of human origin

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900430-7

7 January 2021

Kinetics of erythromycin uptake and release by human lymphocytes and polymorphonuclear leucocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900430-7

7 January 2021

Penetration of macrolides into human polymorphonuclear leucocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900430-7

7 January 2021

Azithromycin inhibition of intracellular Legionella micdadei

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900430-7

7 January 2021

The effect of azithromycin on intracellular Legionella pneumophila in the Mono Mac 6 cell line at serum concentrations attainable in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900430-7

7 January 2021

10.1016/S0924-8579(01)00430-7

Identifiers

DOI

1 reference

26 November 2017

1 reference